CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 10 enrolled
Drug / intervention
Formulation A +1 moredrug
Likely dose
Salicylic acid 1.0% cream applied topically twice daily to one side of faceAI-extracted
Key inclusion· 7
  • Age 13 to 35 years
  • Good health with no other facial skin disorders interfering with acne assessments
  • Minimum 5 inflammatory lesions (papules/pustules) on each side of face with at least one ≥2 mm diameter visible on digital imaging
  • Minimum 5 non-inflammatory lesions (comedones) on each side of face with lesions relatively symmetrical
Key exclusion· 11
  • No inflammatory acne or only non-inflammatory acne
  • Presence of acne cysts or nodules
  • Severe acne forms: acne conglobata, acne fulminans, secondary acne, or acne requiring systemic treatment
  • Excessive facial hair interfering with assessments

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00848744
NCT00848744N/ACompleted

A Split-Face, Paired-Comparison, Pilot Study to Evaluate Safety and Efficacy of Two Topical Salicylic Acid 1.0% Creams for Mild to Moderate Acne Vulgaris

Northwestern University·interventional·Posted Feb 20, 2009·Updated Mar 1, 2018

In Brief

A clinical study evaluating Formulation A and Formulation B for Acne Vulgaris. Completed, enrolled 10 participants across 1 site.

Detailed Summary

This study is a split face, paired-comparison, pilot study of at least 10 subjects to complete. Participants in this study will be patients seen at Children's Memorial Hospital, who are clinically diagnosed with mild to moderate acne vulgaris. Participants will be recruited from one of the clinics, as well as from previous Institutional Review Board (IRB) approved acne studies housed in the Department of Dermatology. All subjects accrued from previous studies have agreed to be contacted for further investigations. Subjects 13 to 35 years of age with mild to moderate acne vulgaris symmetrical in appearance on both sides of the face, and meeting inclusion criteria will be eligible to participate

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesUnited States

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 20, 2009
Enrollment StartFeb 1, 2008
Primary CompletionAug 1, 2008
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 17.4 years ago

Interventions

Formulation Adrug

Formulation A will be applied to the randomly-assigned single (left or right) side of the face twice daily.

Formulation Bdrug

Formulation B will be applied to the randomly-assigned single (left or right) side of the face twice daily.